MS ISSUE FEE PATENT 4614-0107P

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:

STEINAA, Lucilla et al. Conf.:

5928

Appl. No.:

09/806,703

Group:

1644

Filed:

April 30, 2001

Examiner: DIBRINO, M

For:

METHODS FOR THERAPEUTIC VACCINATION

INFORMATION DISCLOSURE STATEMENT (SUBMISSION AFTER NOTICE OF ALLOWANCE BUT PRIOR TO PAYMENT OF THE ISSUE FEE)

U.S. Patent and Trademark Office Customer Service Window - MS ISSUE FEE Randolph Building 401 Dulany Street Alexandria, VA 22314

May 11, 2005

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

Τ. LIST OF PATENTS, PUBLICATIONS, OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449, attached hereto.

II. COPIES

A CD-Rom is attached which contains thereon copies \boxtimes a. of all references listed on the attached PTO-1449 Form, including U.S. patents.

III. CONCISE EXPLANATION OF THE RELEVANCE (check at least one box)

DOCUMENTS IN THE ENGLISH LANGUAGE a.

The patents, publications, or other information 05/18/2005 MBLANCO 00000003 022448 09805703 180.00 DA 01 FC:1806

listed on the attached PTO 1449 are in the English language and therefore, do not require a statement of relevancy.

b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE

A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:

c. ENGLISH LANGUAGE SEARCH REPORT

An English language version of the search report or action that indicates the degree of relevance found by the foreign office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(III)(A)(3).

d. OTHER

The following additional information is provided for the Examiner's consideration.

FEES

IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97(d):

after the mailing date of a Notice of Allowance under § 1.311, but before payment of the Issue Fee.

See the Statement Under 37 C.F.R. § 1.97(e).

V. STATEMENT UNDER 37 C.F.R. § 1.97(e) (check only one box)

The undersigned hereby states that

- a.
 each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than 30 days prior to the filing of this IDS; or
- b.
 each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- c. no item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of the IDS.
- d. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was first cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this the remaining information, to undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application and, best of my knowledge after reasonable inquiry, was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this statement.

VI. PAYMENT OF FEES

Please charge Deposit Account No. 02-2448 in the amount of \$180.00 for the fee required under 37 C.F.R. \$1.97(d) and as set forth in 37 C.F.R. \$1.17(p).

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By #47,604

By Leonard R. Svensson, #30,330

P.O. Box 747

Falls Church, VA 22040-0747

(703) 205-8000

LRS/SWG/sbp 4614-0107P

Attachment(s): 🏻 PTO-1449

Documents

Foreign Search Report

Other: CD-Rom containing references listed on

Moh

PTO-1449 Form

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on:

(Date of Deposit)

BIRCH, STEWART, KOLASCH & BIRCH, LLP

(Date of Signature)



Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

ATTY. DOCKET NO. 4614-0107P APPLICATION NO. 09/806,703

APPLICANT

STEINAA, Lucilla

FILING DATE
April 30, 2001

GROUP 1644

| | | DOCUMEN | |
|--|--|---------|--|
| | | | |
| | | | |
| | | | |

| EXAMINER INITIAL | DOCUMENT NUMBER | Kind | DATE | NAME | CLASS | SUB CLASS | FILING DATE IF APPROPRIATE | |
|---------------------|-----------------|------|---------------|--------------|-------|--------------|-------------------------------|--|
| | US 5,736,142 | | April 7, 1998 | Sette et al. | | | | |
| | US | | _ | | | | | |
| | US | | - | | | | | |
| | US | | | | | | | |
| | US | | | | | | | |
| | US | | | | | | | |
| | US | | - | | | | | |
| | US | | | | | | | |
| | US | | | | | | | |
| | US . | | | | | | | |

FOREIGN PATENT DOCUMENTS

| | Office | DOCUMENT NUMBER | Kind | DATE | COUNTRY | CLASS | SUB CLASS | TRANSLATION | |
|---|--------|--------------------|------|------------|---------|-------|--------------|-------------|----|
| | | | | | | 1 | | YES | NO |
| | WO | 99/40188 | A2 | 1999-08-12 | PCT | | | | |
| | WO | 99/10375 | A2 | 1999-03-04 | PCT | | | | |
| | WO | 98/56919 | A2 | 1998-12-17 | PCT | | | | |
| | | | | | | | | | |
| | | | | | | | | | |
| • | | | | | | | | | |
| | | | | | | | | | - |
| | | | 1 | | | | | | |

OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

WIDMANN, C. et al., "T helper epitopes enhance the cytotoxic...," Journal of Immunological Methods, 155 (1992). pp. 95-99.

ALEXANDER, J. et al., "The optimization of helper t lymphocyte...," Immunologic Research 1998:18/2. pp. 79-92.

STOUTE, J. et al., "A preliminary evaluation of a recombinant...," The New England Journal of Medicine, 1997, Vol. 336 (2).pp. 86-91.

HANKE, T et al., "DNA multi-CTL epitope vaccines...," Vaccine, 1998, Vol. 16, No. 4, pp. 426-435.

GILBERT, S. et al., A protein particle vaccine containing multiple...," Nature Biotechnology, Nov. 1997, Vol. 15, pp. 1280.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.